Presentation on theme: "Drug Promotion And Dealing With The ‘Reps’ Neena Lakhani."— Presentation transcript:
Drug Promotion And Dealing With The ‘Reps’ Neena Lakhani
Introduction Drug Promotion NHS Standards ABPI Code of Practice Company Representatives The ‘meeting’ Evaluating Product Information
Drug promotion by pharmaceutical companies Journal advertisements Mailings Sponsored meetings Gifts Direct-to-consumer advertising Company representative visits
NHS Standards Commercial Sponsorship – Ethical Standards for the NHS (Nov 2000) who is the guidance aimed at? sponsorship, inducements and hospitality research and development potential conflict of interest
Advertising Regulation Advertising is controlled by both: Medicines and Health Regulatory Agency (MHRA) - Statutory (legal) Association of the British Pharmaceutical Industry (ABPI) - Self- regulation
ABPI Code of Practice Applies to 80 UK pharmaceutical companies Covers all areas of promotion by the pharmaceutical industry Not legally binding
Code for Representatives ABPI Code of Practice - covers oral information, as well as written Must be adequately trained Must not give misleading information Must not offer inducement to gain interview Must not cause inconvenience Provision of hospitality
Guidance for Representatives Local policies may exist relating to: Appointment system for meeting clinicians Leaving samples of medicines Sponsorship of educational meetings Frequency of meetings
Why see reps? Freebies! Gather (and give) current and new information Sell company products Inform and educate professionals
Is the information credible? Can be misleading Promotes non-rational prescribing Decreases generic prescribing Increases awareness of new drugs but without the evidence Increases prescribing costs
Some useful facts Oral presentations Written literature
‘The meeting’ What’s in it for me? Be selective By appointment with time limits Be in control Prepare standard questions Beware of bold statements & ‘glossys’
Your 5 Questions 1.What evidence/studies back up the claimed benefit/effect of the drug being promoted? 2.Is the study design valid? 3.Is the result statistically significant? 4.What are the Absolute Risk Reduction (ARR) and the Number Needed to Treat (NNT) to avoid one event over a certain time period? 5.Are the graphs telling the truth? If NO: do you want to continue?
Points to consider: SSafety TTolerability EEffectiveness PPrice One STEP better?
The way forward A policy for seeing reps –? No free lunches? Education meetings with different peer groups Challenge different reps promoting similar products Restrict sponsored events Brush up on critical appraisal skills Use PCT prescribing advisors for unbiased, evidence based information and educational outreach
On line activity Source the following article Evans, J. Establishing Rules of the Road for Pharmaceutical Representatives Fam Pract Manag Mar;12(3): Join the Forum during the next week to discuss and reflect in issues raised the General Practitioner in the article
References Department of Health (2000). Commercial sponsorship – ethical standards for the NHS. alasset/dh_ pdf (accessed July 2011) alasset/dh_ pdf Evans, J. Establishing Rules of the Road for Pharmaceutical Representatives Fam Pract Manag Mar;12(3):10-12.
This work was produced as part of the TIGER project and funded by JISC and the HEA in For further information see: This work by TIGER Project is licensed under a Creative Commons Attribution- NonCommercial-ShareAlike 3.0 Unported License. Based on a work at tiger.library.dmu.ac.uk. tiger.library.dmu.ac.uk The TIGER project has sought to ensure content of the materials comply with a CC BY NC SA licence. Some material links to third party sites and may use a different licence, please check before using. The TIGER project nor any of its partners endorse these sites and cannot be held responsible for their content. Any logos or trademarks in the resource are exclusive property of their owners and their appearance is not an endorsement by the TIGER project.